Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Raloxifene Retards Cartilage Degradation and Improves Subchondral Bone Micro-architecture in Ovariectomized Rats with Patella Baja-Induced- Patellofemoral Joint Osteoarthritis.

< BACK TO ARCHIVE


2020 Mar


Osteoarthritis Cartilage


http://www.ncbi.nlm.nih.gov/pubmed/31326553?dopt=Abstract


28


3

Raloxifene Retards Cartilage Degradation and Improves Subchondral Bone Micro-architecture in Ovariectomized Rats with Patella Baja-Induced- Patellofemoral Joint Osteoarthritis.

Authors

Raloxifene Retards Cartilage Degradation and Improves Subchondral Bone Micro-architecture in Ovariectomized Rats with Patella Baja-Induced- Patellofemoral Joint Osteoarthritis.
Bei M-J, Tian F-M, Xiao Y-P, Cao X-H, Liu N, Zheng Z-Y, Dai M-W, Wang W-Y, Song H-P, Zhang L
Osteoarthritis Cartilage. 2020 Mar; 28(3):344-355.
PMID: 31326553.

Abstract

Abnormal remodeling of subchondral bone (SB) induced by estrogen deficiency has been shown to be involved in osteoarthritis (OA). Raloxifene (RAL) is commonly used to treat postmenopausal osteoporosis (OP). However, little is known about its effects on OA combined with estrogen deficiency. This study was performed to evaluate the efficacy of RAL on patella baja-induced patellofemoral joint OA (PFJOA) in an ovariectomized rat model.
Read This Paper